Menu ×


Preeclampsia Diagnostics Market Analysis by Test Type (Urine Analysis, Blood Tests, and Others); by Product Type {Instruments (Victor 2D Instrument, Auto DELFIA Immunoassay System, and Others), and Consumables}; and by End-User (Hospitals, Specialty Clinics, Diagnostic Centers, Research Centers, and Others) – Global Supply & Demand Analysis & Opportunity Outlook 2023-2033

  • Text Size:

Inflation And Looming Recession to Haunt Businesses:

In 2022 & 2023, market players expected to sail in rough waters; might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain. Further, U.S. economy is expected to grow merely by 3% in 2022.

Request Insights

Purchasing power in the couPurchasing power in the country is expected to fell nearly by 2.5%. On the other hand, European countries to see the worst coming in the form of energy crisis especially in upcoming winters!! Right after COVID-19, inflation has started gripping the economies across the globe. Higher than anticipated inflation, especially in western world had raised concerns for national banks and financial institutions to control the economic loss and safeguard the interest of the businesses. Increased interest rates, strong USD inflated oil prices, looming prices for gas and energy resources due to Ukraine-Russia conflict, China economic slowdown (~4% in 2022) disrupting the production and global supply chain and other factors would impact each industry negatively.                                                         Request Insights

Read More


  • Sera Prognostics, Inc. presented to doctors and patients at the SRI annual meeting the innovative pregnancy protein biomarker information and clinical factor prediction of preeclampsia.
  • Metabolomic Diagnostics has announced its partnership with the US-based biotech firm This partnership is anticipated to bring a novel screening test for preeclampsia risk to the US market by the end of 2022.

Global Preeclampsia Diagnostics Market Highlights Over 2023 - 2033

Base Year


Forecast Year




Base Year Market Size (2022)

 ~ USD 1 Billion

Forecast Year Market Size (2033)

~ USD 4 Billion

The global preeclampsia diagnostics market is estimated to garner a revenue of USD 4 Billion by the end of 2033 by growing at a CAGR of ~13% over the forecast period, i.e., 2023 – 2033. Further, the market generated a revenue of USD 1 Billion in the year 2022. The growth of the market is primarily attributed to the globally rising cases of preeclampsia. For instance, the worldwide occurrence of preeclampsia has reached nearly 5% of all pregnancies.


Get more information on this report: Request Sample PDF

Preeclampsia, also defined as toxemia, is a rapidly complex condition marked by high blood pressure and an excess of protein in pregnant women's urine. It is a hypertensive disorder of pregnancy and a major cause of mortality, long-term frailty, and death in both the unborn baby and the mother. Preeclampsia is most prevalent after the 20th week of pregnancy. For instance, preeclampsia disease accounts for 2% to 9% of pregnancy-related complications, more than 51,000 maternal deaths globally.

Global Preeclampsia Diagnostics Market: Growth Drivers and Challenges

Growth Drivers

  • Increasing Prevalence of Hypertension in Pregnancy – High blood pressure is also known as hypertension that affects the body arteries by making heart to work harder to pump blood. Hypertension in pregnancy needs a regular monitoring to keep the track of raised blood pressure. Therefore, growing cases of hypertension in pregnancy is fueling up the growth of the preeclampsia diagnostics market. It is observed that, an estimated 4% to 11% of all pregnancies are complicated by hypertension in pregnancy.
  • Upsurge in the Occurrence of Placenta Previa – For instance, the issue of placenta previa is affecting nearly 1% to 4% of third-trimester pregnancies.
  • Rising Development Activities for New Tests to Detect Biomarkers Indicating Preeclampsia – As per a clinical study, in women with subclinical preeclampsia, gestational hypertension, essential hypertension, or moderate preeclampsia, a combination of CT-pro-ET1, sFlt-1, and systolic blood pressure formed sensitivity of 80% and precision of 90% for the development of severe preeclampsia within 1 week. Thus, ET-1 or its byproduct protein CT-pro-ET1 may be advantageous in disease prediction or treatment planning.
  • Escalation in Receiving Prenatal Care – As per the data provided by the World Bank, in 2019 88% of pregnant women received prenatal care across the globe.   
  • Globally Increasing Healthcare Expenditure – According to the World Bank, in 2019, worldwide healthcare expenditure increased by 9.83%.


  • Lack of Awareness About Preeclampsia
  • Very Late Detection of Preeclampsia Disorder
  • Unavailability of Preeclampsia Diagnostic Products

The global preeclampsia diagnostics market is segmented and analyzed for demand and supply by test type into urine analysis, blood tests, and others. Out of these, the blood tests segment is anticipated to garner the largest market share over the forecast period owing to the accuracy of blood tests in efficiently detecting the biomarkers, and rising number of blood tests types which have been introducing in the market. For instance, in England, few newer blood tests were introduced to detect the preeclampsia under the guidance of related governmental bodies. DELFIA Xpress PLGF 1-2-3, Delfia Xpress sFlt-1/Xpress PLGF1-2-3 ratio, Elecsys immunoassay sFlt-1/PLGF ratio, and Triage PLGF Test are the four tests recommended in the guidelines in first half of 2022.

Major Macro-Economic Indicators Impacting the Market Growth


According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.

Global Preeclampsia Diagnostics Market Regional Synopsis

Regionally, the global preeclampsia diagnostics market is studied into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Amongst these markets, the market in North America is projected to hold the largest market share by the end of 2033 backed by the rising adoption of highly advanced products, growing awareness among people regarding the preeclampsia, upsurge in development of diagnostic tests, growing prevalence of pregnancy related disorders, and cumulative healthcare expenditure in the region. According to a clinical study, over the last 12 years, in the United States, the rate of high blood pressure-related diseases among pregnant women have more than doubled, rising from 38% per 1,000 live births in 2007 to 78% in 2019.


The global preeclampsia diagnostics market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC (Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook

Market Segmentation

Our in-depth analysis of the global preeclampsia diagnostics market includes the following segments:

By Test Type

  • Urine Analysis
  • Blood Tests
  • Others

By Product Type

  • Instruments
    • Victor 2D Instrument
    • AutoDELFIA Immunoassay System
    • Others
  • Consumables

By End-User

  • Hospitals
  • Specialty Clinics
  • Diagnostic Centers
  • Research Centers
  • Others
Top Featured Companies Dominating the Global Preeclampsia Diagnostics Market
  • F. Hoffmann-La Roche Ltd
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis
  • PerkinElmer, Inc.
  • Diabetomics, Inc.
  • Thermo Fisher Scientific Holdings, Inc.
  • Metabolomic Diagnostics
  • DRG Instruments GmbH
  • Sera Prognostics, Inc.
  • Bayer AG
  • MOMM Diagnostics
  • Siemens Healthcare GmbH



Related Reports

Disclaimer | Privacy Policy | Terms & Conditions | LOB

Copyright © 2022 Research Nester. All Rights Reserved